참고문헌
- Schiff ER, Maddrey WC, Sorrell MF. Schiff's diseases of the liver. Philadelphia: Lippincott-Raven Publishers; 1999. p. 1281-304.
- Kew MC. Hepatic tumors and cysts. Sleisenger & Fordtran's gastrointestinal and liver disease: pathology/diagnosis/management. Philadelphia: Saunders; 1998. p. 1365-87.
- Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer research. 1987;47(18):4967-72.
- Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997;350(9085):1142-3.
- Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet. 1998;351(9097):214-5.
- El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33(1):62-5. https://doi.org/10.1053/jhep.2001.21041
- Hu KQ. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med. 2002;139(4):234-43. https://doi.org/10.1067/mlc.2002.122281
- Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest. 1997;100(6):1325-9. https://doi.org/10.1172/JCI119651
- Buttar NS, Wang KK, editors. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors. Mayo Clin Proc. 2000;75(10):1027-38. https://doi.org/10.4065/75.10.1027
- Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37(5):431-502. https://doi.org/10.1080/10408360091174286
- Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8(3):289-93. https://doi.org/10.1038/nm0302-289
- Cheng J, Imanishi H, Iijima H, Shimomura S, Yamamoto T, Amuro Y, et al. Expression of cyclooxygenase 2 and cytosolic phospholipase A(2) in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol Res. 2002;23(3):185-95. https://doi.org/10.1016/S1386-6346(01)00177-2
-
Weddle DL, Tithoff P, Williams M, Schuller HM.
${\beta}$ -adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis. 2001;22(3):473-9. https://doi.org/10.1093/carcin/22.3.473 - Davies G, Martin LA, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 2002;13(5):669-78. https://doi.org/10.1093/annonc/mdf125
- Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000;30(2):73-81. https://doi.org/10.1016/S0169-5002(00)00132-X
-
Seno H, Oshima M, Ishikawa T-o, Oshima H, Takaku K, Chiba T, et al. Cyclooxygenase 2-and prostaglandin
$E_2$ receptor$EP_2$ -dependent angiogenesis in$Apc^{{\Delta}716}$ mouse intestinal polyps. Cancer research. 2002;62(2):506-11. - Richter M, Weiss M, Weinberger I, Fürstenberger G, Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis. 2001;22(1):17-25. https://doi.org/10.1093/carcin/22.1.17
- Wu GS, Zou SQ, Liu ZR, Tang ZH, Wang JH. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol. 2003;9(6):1302-6. https://doi.org/10.3748/wjg.v9.i6.1302
- Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294(5548):1871-5. https://doi.org/10.1126/science.294.5548.1871
- Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122(5):518-23.
- Harizi H, Gualde N. The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens. 2005;65(6):507-14. https://doi.org/10.1111/j.1399-0039.2005.00394.x
-
Karin M. Nuclear factor-
${\kappa}B$ in cancer development and progression. Nature. 2006;441(7092):431-6. https://doi.org/10.1038/nature04870 - Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99. https://doi.org/10.1016/j.cell.2010.01.025
- Cheng J, Imanishi H, Amuro Y, Hada T. Ns-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer. 2002;99(5):755-61. https://doi.org/10.1002/ijc.10409
- Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clinical cancer research. 2005;11(22):8213-21. https://doi.org/10.1158/1078-0432.CCR-05-1044
-
Heiduschka G, Erovic BM, Vormittag L, Skoda C, Martinek H, Brunner M, et al.
$7{\beta}$ -hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2009;135(3):261-7. https://doi.org/10.1001/archoto.2008.558 - Park W, Oh YT, Han JH, Pyo H. Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2. J Exp Clin Cancer Res. 2008;27(1):66. https://doi.org/10.1186/1756-9966-27-66
- Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer. 2007;97(11):1523-31. https://doi.org/10.1038/sj.bjc.6604057
- Futaki N, Arai I, Hamasaka Y, Takahashi S, Higuchi S, Otomo S. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol. 1993;45(8):753-5. https://doi.org/10.1111/j.2042-7158.1993.tb07103.x
- Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther. 1990;254(1):180-7.
- Mejza F, Nizankowska E. [Selective inhibitors of cyclooxygenase-2 (COX-2)]. Postepy Hig Med Dosw. 2001;55(2):287-302. Polish.
- Zarghi A, Sabakhi I, Topuzyan V, Hajimahdi Z, Daraie B. Design, synthesis and biological evaluation of 5-oxo-1, 4, 5, 6, 7, 8 hexahydroquinoline derivatives as selective cyclooxygenase-2 inhibitors. Iran J Pharm Res. 2014;13:61-9. https://doi.org/10.18579/jpcrkc/2014/13/2/78403
- Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18(55):7908-16. https://doi.org/10.1038/sj.onc.1203286
- Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology. 1999;29(3):688-96. https://doi.org/10.1002/hep.510290355
- Hu KQ, Yu CH, Mineyama Y, McCracken JD, Hillebrand DJ, Hasan M. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. Int J Oncol. 2003;22(4):757-63.
- Rahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H, Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res. 2000;60(8):2085-9.
- Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res. 2001;7(5):1410-8.
-
Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the
$NF-{\kappa}B$ pathway. J Biol Chem. 1999;274(38):27307-14. https://doi.org/10.1074/jbc.274.38.27307 - Herrmann C, Block C, Geisen C, Haas K, Weber C, Winde G, et al. Sulindac sulfide inhibits Ras signaling. Oncogene. 1998;17(14):1769-76. https://doi.org/10.1038/sj.onc.1202085
- Waddell WR, Miesfeld RL. Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: the effect of sulindac. J Surg Oncol. 1995;58(4):252-6. https://doi.org/10.1002/jso.2930580411
- Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, et al. Apoptosis primarily accounts for the growthinhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxy-genase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997;57(12):2452-9.
- Park MK, Kim MK, Kim JC, Sung YK. Pattern of apoptosis by NS398, a selective COX-2 inhibitor, in hepatocellular carcinoma cell lines. Cancer Res Treat. 2005;37(5):313-7. https://doi.org/10.4143/crt.2005.37.5.313
- Cheng AS, Chan HL, Leung WK, Wong N, Johnson PJ, Sung JJ. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Oncol. 2003;23(1):113-9.